French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

Annals of the Rheumatic Diseases

Volumn 62, Issue 8, 2003, Pages 791-

  Mariette, X ^a,b   Salmon, D ^b  

^a BICÊTRE HOSPITAL   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ETHAMBUTOL; GLUCOCORTICOID; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

BCG VACCINATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG INDICATION; FRANCE; HUMAN; LATENT PERIOD; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT PLANNING; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; FRANCE; HUMANS; PRACTICE GUIDELINES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242416978     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.8.791     Document Type: Letter

References (4)

1. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61(suppl II):ii62-3.
2. Salmon D on behalf of the GTI and AFSSAPS. Recommandations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002;69:170-2.
3. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-92.
4. Khan K, Muennig P, Behta M, Graff Zivin J. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;23:1850-66.